Ron Cooper Named Chairman of C4 Therapeutics Board

C4 Therapeutics, Inc. (C4T) has announced significant changes to its Board of Directors as part of its strategy to evolve into a fully integrated biotechnology firm. Ron Cooper, a seasoned global biopharmaceutical leader, has been appointed as the new Chairman of the Board. Bruce Downey, who chaired the board from June 2022 to June 2024, will continue to serve as a board member and as the Chair of the Organization, Leadership, and Compensation Committee. Meanwhile, Glenn Dubin, who joined the board in 2021, has opted to step down.

Ron Cooper brings a wealth of experience from his extensive career in the pharmaceutical sector. He most recently served as the President and CEO of Albireo Pharma, where he contributed to the company's growth before it was acquired by Ipsen in March 2023. His previous tenure at Bristol-Myers Squibb (BMS) saw him hold various roles with increasing responsibilities, culminating in his position as President of the European division. At BMS, Cooper was instrumental in several successful product launches, including Abilify®, Atripla®, Eliquis®, Plavix®, Sprycel®, and Yervoy®. Currently, he also serves on the Board of Directors for Generation Bio.

In his new role, Cooper aims to leverage his background in building integrated biopharmaceutical companies to advance C4T’s mission in targeted protein degradation. This scientific approach focuses on utilizing the body's natural protein recycling mechanisms to degrade disease-causing proteins, which could provide new treatment options for difficult-to-treat diseases and potentially overcome drug resistance.

Bruce Downey expressed his satisfaction with the board’s broadened expertise during his tenure as chairman. He looks forward to working closely with Cooper and the rest of the board to help C4T seize upcoming opportunities. Downey also acknowledged Glenn Dubin's contributions as he steps down, expressing gratitude for his support and wishing him well.

Andrew Hirsch, President and CEO of C4 Therapeutics, emphasized the significance of Cooper’s appointment. He highlighted the value of Cooper’s experience in guiding companies through the stages of discovery, development, and commercialization of products. Hirsch noted that the company is enthusiastic about the future and remains committed to advancing its pipeline to fulfill the potential of targeted protein degradation for patients in need of new therapies.

C4 Therapeutics is a clinical-stage biopharmaceutical company committed to developing a new generation of medicines through targeted protein degradation. The company is currently progressing its oncology programs through clinical trials, utilizing its TORPEDO® platform to design and optimize small-molecule medicines aimed at challenging diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!